Dianthus Therapeutics, Inc. DNTH
86.03 USD +3.02 (+3.64%)
At closeNov 9, 2026, 4:00 AM EST
88.00 +1.97 +2.29%
Pre-market · Nov 9, 4:00 AM ET
82.13 Day range 87.44
34.29 52-week range 117.88
- YTD
- +108.76%
- 1 year
- +136.15%
News
zacks.com Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.
globenewswire.com Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic…
globenewswire.com Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
globenewswire.com Dianthus Therapeutics to Participate in Five Investor Conferences During November NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
benzinga.com This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
benzinga.com Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113 Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
benzinga.com HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $158 price target.